FOXO4-DRI (also known as FOXO4-related D-Retro-Inverso peptide) is a synthetic peptide designed to induce selective apoptosis (programmed cell death) in senescent cells. Senescent cells are “zombie cells” that stop dividing but remain metabolically active, contributing to aging, inflammation, and age-related diseases like cancer, neurodegeneration, and cardiovascular issues. Developed by researchers at Erasmus University Medical Center (led by Peter de Keizer’s team), it was first detailed in a 2017 Cell journal paper titled “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging”.

Mechanism of Action

• Targets FOXO4: FOXO4 is a transcription factor overexpressed in senescent cells. It interacts with p53 (a tumor suppressor protein) in the nucleus, preventing p53 from triggering apoptosis.
• D-Retro-Inverso Design: The peptide is a mirror-image version of the FOXO4-p53 binding domain (made with D-amino acids, reversed sequence). This makes it protease-resistant (stable in blood) and allows it to:
  1. Enter senescent cells via endocytosis.
  2. Competitively bind nuclear FOXO4.
  3. Release p53, which then translocates to mitochondria.
  4. Induce cytochrome C release → caspase activation → apoptosis selectively in senescent cells (healthy cells are spared due to lower FOXO4/p53 interaction).
• Evidence: In mouse models (progeroid, naturally aged, chemotherapy-treated), subcutaneous injections (e.g., 25 mg/kg weekly) cleared senescent cells, improved tissue function (fur regrowth, kidney filtration), extended lifespan by ~25% in fast-aging mice, and reduced chemotherapy side effects without toxicity.

Key Studies & Evidence

• Human Relevance: Works on human senescent cells in vitro. No large-scale human trials yet (as of 2024), but preclinical data suggests potential for “senolytics” therapy.

Availability & Status

• Not FDA-Approved: Experimental/research compound only. Not for human therapeutic use.
• Research Sources: Available from peptide suppliers (e.g., >95% purity HPLC/MS-verified) for lab use (~$100-300 for 5-10 mg). Sequences: Ac-RRMKWKKENNRIEFRKKWRSW-amide (D-retro-inverso).
• Caveats:
  • Potential off-target effects (e.g., mild weight loss in mice).
  • Self-administration risky (dosing unoptimized for humans; possible immunogenicity).
  • Ongoing research: Variants like improved DRI peptides or combinations with dasatinib/quercetin (other senolytics).

Potential Applications

• Anti-Aging: Clearing senescent cells to rejuvenate tissues.
• Cancer: Adjunct to chemo to mitigate damage and target therapy-resistant senescent tumor cells.
• Fibrosis/Degeneration: E.g., idiopathic pulmonary fibrosis, osteoarthritis.

For latest updates, check PubMed (search “FOXO4-DRI senolytic”) or clinicaltrials.gov (none active yet). If you’re researching, source from reputable labs like GenScript or Peptide Sciences. Always consult experts for experimental use.